Items where authors include "Heymann, M-F."
Article
Dumars, C., Foubert, F., Touchefeu, Y. et al. (4 more authors) (2016) Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors? Endocrine. ISSN 1355-008X
Davaine, J-M., Quillard, T., Chatelais, M. et al. (7 more authors) (2016) Bone Like Arterial Calcification in Femoral Atherosclerotic Lesions: Prevalence and Role of Osteoprotegerin and Pericytes. European Journal of Vascular and Endovascular Surgery, 51 (2). pp. 259-267. ISSN 1078-5884
Heymann, M-F., Renema, N. and Heymann, D. orcid.org/0000-0001-7777-0669 (2015) Alpelisib. Phosphatidylinositol 3-kinase alpha (PI3K alpha) inhibitor Oncolytic. Drugs of the Future, 40 (4). pp. 213-223. ISSN 0377-8282
Segaliny, A.I., Tellez-Gabriel, M., Heymann, M-F. et al. (1 more author) (2015) Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. JOURNAL OF BONE ONCOLOGY, 4 (1). pp. 1-12. ISSN 2212-1374
Davaine, J-M., Quillard, T., Brion, R. et al. (10 more authors) (2014) Osteoprotegerin, Pericytes and Bone-Like Vascular Calcification Are Associated with Carotid Plaque Stability. PLoS ONE, 9 (9). e107642. ISSN 1932-6203
Teletchea, S., Stresing, V., Hervouet, S. et al. (6 more authors) (2014) Novel RANK Antagonists for the Treatment of Bone-Resorptive Disease: Theoretical Predictions and Experimental Validation. Journal of Bone and Mineral Research, 29 (6). pp. 1466-1477. ISSN 0884-0431
Monderer, D., Luseau, A., Bellec, A. et al. (14 more authors) (2013) New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Laboratory Investigation, 93 (10). pp. 1100-1114. ISSN 0023-6837
Baud'huin, M.E., Duplomb, L., Teletchea, S. et al. (6 more authors) (2013) Osteoprotegerin: multiple partners for multiple functions. Cytokine and Growth Factor Reviews, 24 (5). pp. 401-409. ISSN 1359-6101
Redini, F., Odri, G.A., Picarda, G. et al. (4 more authors) (2013) Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? Expert Opinion on Emerging Drugs, 18 (3). pp. 339-352. ISSN 1472-8214
Picarda, G., Matous, E., Amiaud, J. et al. (8 more authors) (2013) Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL. Journal of Bone Oncology, 2 (3). pp. 95-104. ISSN 2212-1374
Miot-Noirault, E., David, E., Vidal, A. et al. (8 more authors) (2013) Tc-99m-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model. EJNMMI Research, 3. 40. ISSN 2191-219X
Heymann, M-F., Herisson, F., Davaine, J-M. et al. (6 more authors) (2012) Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: Comparison between carotid and femoral beds. Cytokine, 58 (2). pp. 300-306. ISSN 1043-4666
Battaglia, S., Dumoucel, S., Chesneau, J. et al. (6 more authors) (2011) Impact of Oncopediatric Dosing Regimen of Zoledronic Acid on Bone Growth: Preclinical Studies and Case Report of an Osteosarcoma Pediatric Patient. Journal of Bone and Mineral Research, 26 (10). pp. 2439-2451. ISSN 0884-0431
Herisson, F., Heymann, M-F., Chetiveaux, M. et al. (8 more authors) (2011) Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis, 216 (2). pp. 348-354. ISSN 0021-9150
Perrot, P., Rousseau, J., Bouffaut, A-L. et al. (8 more authors) (2010) Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence. PLOS ONE, 5 (6). e10999. ISSN 1932-6203
Heymann, M-F., Riet, A., Le Goff, B. et al. (3 more authors) (2008) OPG, RANK and RANK ligand expression in thyroid lesions. Regulatory Peptides, 148 (1-3). pp. 46-53. ISSN 0167-0115
Lamoureux, F., Ory, B., Battaglia, S. et al. (6 more authors) (2008) Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. International Journal of Cancer, 122 (4). pp. 751-760. ISSN 0020-7136